ArticleTranslational lung cancer research2025
Syndrome of inappropriate secretion of antidiuretic hormone (SIADH) by osimertinib and continued treatment with dose reduction for postoperative recurrence of lung adenocarcinoma: a case report.
Article in Translational lung cancer research, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Osimertinib is the standard third-generation epidermal growth factor receptor tyrosine kinase inhibitor (EGFR-TKI) of choice for Case Description: An 80-year-old man with a history of hypertension, diabetes mellitus, and partial right nephrectomy for right renal cell carcinoma, but with preserved renal function, underwent thoracoscopic left upper lobectomy in 2013 for lung adenocarcinoma with the Conclusions: This case suggests that osimertinib treatment can be continued with dose reduction in lung adenocarcinoma patients who develop SIADH, especially when alternative treatment options are limited.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.